| Name | Title | Contact Details |
|---|
Miami Medical is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Westline Medical Management is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ivek Corp. is a North Springfield, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Olympus, we put a lot of good back into the world, and what we do, really matters. We are committed to making people`s lives healthier, safer and more fulfilling every day by crafting innovative optical and digital solutions in medical technologies; life sciences; industrial solutions; and cameras and audio products. Everything we do at Olympus is a reflection of our vision, and everyone here helps to make it a reality. We view our relationship with and commitment to our employees with the same passion. Everything we do at Olympus is a reflection of our purpose and everyone here helps to make it a reality. We`re invested in our employees, great ideas, and how they impact the communities around us. We see the world through multiple lenses and come together to find the right answers; the best solutions. Olympus Corporation of the Americas (OCA)—a wholly owned subsidiary of Olympus Corporation in Tokyo, Japan—is headquartered in Center Valley, Pennsylvania, and employs more than 5,300 people at our locations throughout North and South America. Join us!
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.